Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics granted 59,700 stock options as Nasdaq-compliant inducement awards to three new employees with multi-year vesting.

Rhea-AI Summary

Cartesian Therapeutics (RNAC) granted stock option inducement awards to three new employees, effective September 4, 2026.

The awards cover options to purchase an aggregate of 59,700 shares of common stock at an exercise price of $9.27 per share, equal to the closing price on the Nasdaq Global Market on the grant date. The options were issued under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan, approved by the board of directors, and granted under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.

The options vest 25% on September 4, 2027, with the remaining 75% vesting in 36 substantially equal monthly installments until full vesting on September 4, 2030, and have a ten-year term.

Market Context

The Aug 7 inducement announcement covered 115,250 shares under the same plan, compared with 59,700 s...

Analysis

The Aug 7 inducement announcement covered 115,250 shares under the same plan, compared with 59,700 shares in the current grant to three employees.

Key Figures

Option Shares: 59,700 shares Exercise Price: $9.27 Initial Vesting: 25% +2 more

Option Shares

59,700 shares

Aggregate options granted to three new employees

Exercise Price

$9.27

Per share; equal to the closing price on the grant date

Initial Vesting

25%

Vests on September 4, 2027

Full Vesting

September 4, 2030

After 36 substantially equal monthly installments

Option Term

10 years

Term of the employment inducement options

Historical Context

3 past events · Latest: Aug 07

3 events

1. Aug 07

   Employment inducement grants

   24h Move

   +1.0%

   Four employees received options under the same inducement plan with four-year vesting.

2. Jul 02

   Employment inducement grants

   24h Move

   +4.0%

   Eight employees received options under the same plan with 36-month installment vesting.

3. Jun 12

   Employment inducement grant

   24h Move

   -9.6%

   One employee received an option under Nasdaq Rule 5635(c)(4).

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On September 4, 2026, the Company issued to these employees options to purchase an aggregate of 59,700 shares of the Company’s common stock with an exercise price of $9.27, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on September 4, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on September 4, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com